AparciMIsilakZUzOYalcinMKucukU. Endocan and Endothelial Dysfunction. Angiology. 2015;66(5):488–489.
2.
BaltaSMikhailidisDPDemirkolS. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–777.
3.
UnluMKaramanMAySA. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin Exp Hypertens. 2013;35(6):418–423.
4.
KaramanMBaltaSAySA. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013;35(7):516–522.
5.
OzturkCBaltaSBaltaI. Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with behcet disease without cardiovascular involvement. Angiology. 2015;66(3):291–296.
6.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291–296.
7.
BaltaIBaltaSDemirkolS. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–1070.
8.
CelıkTBaltaSKaramanM. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015;24(1):55–60.
9.
AthyrosVGKakafikaAIKaragiannisAMikhailidisDP. Do we need to consider inflammatory markers when we treat atherosclerotic disease?Atherosclerosis. 2008;200(1):1–12.
